Global Health Limited Releases Q4 FY26 Earnings Call Transcript
Global Health Limited (Medanta) released its Q4 FY26 earnings call transcript. For FY26, total income grew 20% to ₹45,089 million, and PAT increased 15.1% to ₹5,541 million. Q4 FY26 revenue grew 25% to ₹11,958 million, with PAT up 40% to ₹1,417 million. The company plans to add ~500 beds short-term and 2,700 via greenfield projects over 3-4 years.
The release of an earnings call transcript, which contains detailed financial results and future outlook, is material information for investors and analysts, impacting investment decisions.
The announcement is a factual release of an earnings call transcript, providing financial results and operational updates without expressing overly positive or negative opinions.
Global Health Limited (Medanta) has released the transcript of its Earnings Conference Call held on May 15, 2026, to discuss the results for the Fourth Quarter and Financial Year ended March 31, 2026. The transcript is available on the company's investor relations website.
During the call, the management highlighted key milestones and performance for FY2026. The company's 550-bed Noida facility commenced operations, and land was acquired for a 400+ bed hospital in Guwahati and a 400+ bed hospital in Varanasi. Medanta Gurugram was recognized by Newsweek as the best hospital in India for the seventh consecutive year and remains among the top 150 hospitals globally. The Lucknow hospital received JCI accreditation, and the Noida hospital secured NABH accreditation within six months of operations.
Financially, for FY2026, total income grew by 20% year-on-year to ₹45,089 million, with EBITDA growing by 19% to ₹11,343 million (excluding Noida). Consolidated profit after tax increased by 15.1% to ₹5,541 million. The Board recommended a final dividend of ₹0.50 per share. Total bed capacity increased by 20.5% with the addition of 623 beds. Inpatient count increased by 16% and outpatient count by 19% year-on-year.
For Q4 FY26, total income grew by 25% year-on-year to ₹11,958 million, and EBITDA grew by 17% to ₹2,906 million (including Noida). Profit after tax for the quarter increased by 40% to ₹1,417 million. Occupied bed days increased by 18% year-on-year.
The company also provided an update on its expansion pipeline, expecting to add approximately 500 beds across existing hospitals in the short term and around 2,700 beds through five greenfield projects over the next 3 to 4 years. Total project capex over the next five years is estimated at approximately ₹45,000 million. The company ended FY2026 with a net cash position of ₹5,906 million.
What to do with a filing like this
Global Health Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Global Health Limited. Read the original for the full detail.